Research Project
Grant-in-Aid for Scientific Research (C)
High expression of CD30 and JunB is characteristic of tumor cells in anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma (HL). The possible inter-relationships of CD30 and JunB were examined in this study. We found that the CD30 promoter in tumor cells of both nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) positive and NPM-ALK negative ALCL and HL is regulated by a constitutively active CD30-extracellular signal-regulated kinase (ERK) 1/2 mitogen-activated protein kinase (MAPK). Phosphorylated ERK1/2 MAPK was confirmed in nuclei of tumor cells in biopsies of ALCL and HL. CD30-ERK1/2 MAPK signals induce JunB expression which maintains high activity of the CD30 promoter. JunB induction appears to be largely independent of NF-KB in ALCL and HL. These results demonstrate a common mechanism of CD30 overexpression in ALCL and HL although the results of CD30 signaling differ between NPM- ALK positive ALCL and other subgroups ; NPM-ALK negative ALCL, cutaneous ALCL and HL as we recently reported.
All 2007 2006
All Journal Article (21 results) (of which Peer Reviewed: 10 results) Presentation (2 results)
Cancer Lett 257
Pages: 206-215
Microbes Infect 48
Pages: 721-728
Lab Invest 87
Pages: 372-382
Cancer Lett 257(2)
Pages: 206-15
Pages: 721-8
Pages: 372-82
Cancer Lett. 257
Microbes Infect. 48
Lab Invest. 87
Leukemia 20(5)
Pages: 800-6
Drug News Perspect 19(4)
Pages: 201-9
Int J Cancer 118(5)
Pages: 1098-107
Leuk Res 30(1)
Pages: 90-7
Leukemia 20
Pages: 800-806
Drug News Perspect
Pages: 201-209
Int J Cancer 118
Pages: 1098-1107
Leuk Res 30
Pages: 90-97
Int J Cancer. 118(5)
Leuk Res. 30(1)